Bruker Corporation

Análisis de la acción Bruker Corporation (BRKR)

$55.370

+0.576 (+1.04%)Al cierre

Loading chart…
Máximo
56.200
Apertura
54.890
Precio medio ponderado por volumen
55.42
Volumen
1.91M
Capitalización
9.72B
Mínimo
54.680
Importe
105.95M
EV/EBITDA, TTM
16.91

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.

www.bruker.com

Análisis de IA of Bruker Corporation (BRKR)

Mantener

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

Recomendaciones de analistas (14)

-5.76% Potencial de caída
Mantener
2 Comprar
10 Mantener
2 Vender
Actual: 55.37
Mínimo
40.00
Promedio
52.18
Máximo
60.00

Barclays

2026-10-07

Precio objetivo

$70

Sobreponderar

Guggenheim

2026-10-01

Precio objetivo

$72

Comprar

Leerink

2026-09-29

Precio objetivo

$80

Superar al mercado

UBS

2026-09-09

Precio objetivo

$65

Neutral

TD Cowen

2026-07-15

Precio objetivo

$60

Mantener

Métricas de valoración

El PER previsto actual de Bruker Corporation (BRKR) es 13.83, frente a su media de 5 años de 23.47.

PER previsto

Infravalorado
Media 5A P/E
23.47
P/E actual
13.83
Sobrevalorada
29.56
Infravalorada
17.38

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
17.55
EV/EBITDA actual
16.91
Sobrevalorada
21.12
Infravalorada
13.98

Precio/ventas previsto

Valor razonable
Media 5A P/S
2.90
P/S actual
2.25
Sobrevalorada
3.81
Infravalorada
1.99

Escenarios de precio de Alphio AI para BRKR

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BRKR

$53.26

Precio del escenario

B

Base

Base · 50%BRKR

$44.40

Precio del escenario

B

Bajista

Bajista · 25%BRKR

$41.00

Precio del escenario

Ballenas con BRKR en cartera

B

Becker Capital Management Inc

+ Con en carteraBRKR

+4.10%

Rentabilidad a 3 meses

S

Steadfast Capital Management LP

+ Con en carteraBRKR

+1.78%

Rentabilidad a 3 meses

C

Cornerstone Investment Partners, LLC

+ Con en carteraBRKR

+1.13%

Rentabilidad a 3 meses

E

Eversept Partners, L.P.

+ Con en carteraBRKR

-9.17%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-06 (ET)

07:30:00

Bruker Releases Draft Atlas of Human Plasma Proteome

2026-09-28 (ET)

07:30:00

Bruker Corporation Unveils New Protein Analysis Workflows

2026-09-21 (ET)

07:30:00

Bruker Corporation Secures Over $6M NMR Order from UC Berkeley

2026-09-04 (ET)

05:30:00

Bruker and Luvata Announce Strategic Collaboration

Noticias

Preguntas frecuentes sobre BRKR, respondidas por Alphio AI

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar